Dashboard
Manage Tickers

INSMINSMED Inc

Nasdaq insmed.com


$ 23.92 $ -0.14 (-0.58 %)    

Thursday, 23-May-2024 13:18:46 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 454.82 $ -4.25 (-0.92 %)
DIA $ 398.57 $ -4.29 (-1.08 %)
SPY $ 530.36 $ -3.92 (-0.74 %)
TLT $ 91.26 $ -0.74 (-0.8 %)
GLD $ 225.37 $ -2.58 (-1.18 %)
$ 24.16
$ 24.06
$ 0.00 x 0
$ 23.89 x 100
$ 23.73 - $ 24.07
$ 18.31 - $ 32.00
1,660,550
na
3.59B
$ 1.29
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 02-22-2024 12-31-2023 10-K
3 10-26-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-23-2023 12-31-2022 10-K
7 10-27-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 02-17-2022 12-31-2021 10-K
11 10-28-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 10-29-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 04-30-2020 03-31-2020 10-Q
18 02-25-2020 12-31-2019 10-K
19 10-30-2019 09-30-2019 10-Q
20 08-01-2019 06-30-2019 10-Q
21 05-07-2019 03-31-2019 10-Q
22 02-22-2019 12-31-2018 10-K
23 10-30-2018 09-30-2018 10-Q
24 08-02-2018 06-30-2018 10-Q
25 05-02-2018 03-31-2018 10-Q
26 02-23-2018 12-31-2017 10-K
27 11-02-2017 09-30-2017 10-Q
28 08-03-2017 06-30-2017 10-Q
29 05-03-2017 03-31-2017 10-Q
30 02-23-2017 12-31-2016 10-K
31 11-03-2016 09-30-2016 10-Q
32 08-04-2016 06-30-2016 10-Q
33 05-05-2016 03-31-2016 10-Q
34 02-25-2016 12-31-2015 10-K
35 11-06-2015 09-30-2015 10-Q
36 08-06-2015 06-30-2015 10-Q
37 05-07-2015 03-31-2015 10-Q
38 02-27-2015 12-31-2014 10-K
39 11-06-2014 09-30-2014 10-Q
40 08-06-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

insmed-presents-patient-reported-outcomes-and-microbiologic-data-from-phase-3-arise-study-of-arikayce-in-patients-with-ntm-lung-disease-caused-by-mac-at-american-thoracic-society-2024-international-conference-plenary-session
Insmed Presents Patient-Reported Outcomes ...
05/20/2024 20:29:32

—Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Greater Improvements in Respiratory Sy...

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
05/17/2024 17:35:23

truist-securities-maintains-buy-on-insmed-maintains-48-price-target
Truist Securities Maintains Buy on Insmed,...
05/16/2024 17:20:54

Truist Securities analyst Nicole Germino maintains Insmed (NASDAQ:INSM) with a Buy and maintains $48 price target.

dell-to-rally-over-13-here-are-10-top-analyst-forecasts-for-wednesday
Dell To Rally Over 13%? Here Are 10 Top An...
05/15/2024 11:50:22

goldman-sachs-maintains-buy-on-insmed-raises-price-target-to-49
Goldman Sachs Maintains Buy on Insmed, Rai...
05/15/2024 11:23:14

Goldman Sachs analyst Andrea Tan maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $40 to $49.

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
05/14/2024 17:35:24

hc-wainwright--co-reiterates-buy-on-insmed-maintains-52-price-target
HC Wainwright & Co. Reiterates Buy on Insm...
05/14/2024 11:22:01

HC Wainwright & Co. analyst Andrew Fein reiterates Insmed (NASDAQ:INSM) with a Buy and maintains $52 price target.

mizuho-maintains-buy-on-insmed-raises-price-target-to-36
Mizuho Maintains Buy on Insmed, Raises Pri...
05/13/2024 13:49:32

Mizuho analyst Graig Suvannavejh maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $35 to $36.

morgan-stanley-maintains-overweight-on-insmed-raises-price-target-to-43
Morgan Stanley Maintains Overweight on Ins...
05/10/2024 15:38:56

Morgan Stanley analyst Matthew Harrison maintains Insmed (NASDAQ:INSM) with a Overweight and raises the price target from $4...

insmed-reiterated-2024-global-arikayce-revenue-guidance-of-340m-360m
Insmed Reiterated 2024 Global ARIKAYCE Rev...
05/09/2024 11:24:17

Insmed is reiterating its sales guidance for full-year 2024 global ARIKAYCE revenues in the range of $340 million to $360 mil...

insmed-q1-2024-gaap-eps-106-beats-123-estimate-sales-75500m-miss-77758m-estimate
Insmed Q1 2024 GAAP EPS $(1.06) Beats $(1....
05/09/2024 11:09:37

Insmed (NASDAQ:INSM) reported quarterly losses of $(1.06) per share which beat the analyst consensus estimate of $(1.23) by 13....

truist-securities-initiates-coverage-on-insmed-with-buy-rating-announces-price-target-of-48
Truist Securities Initiates Coverage On In...
04/23/2024 10:40:10

Truist Securities analyst Nicole Germino initiates coverage on Insmed (NASDAQ:INSM) with a Buy rating and announces Price Ta...

barclays-maintains-overweight-on-insmed-raises-price-target-to-40
Barclays Maintains Overweight on Insmed, R...
04/11/2024 13:29:58

Barclays analyst Leon Wang maintains Insmed (NASDAQ:INSM) with a Overweight and raises the price target from $37 to $40.

insmed-shares-are-trading-higher-after-wells-fargo-maintained-an-overweight-rating-on-the-stock-and-maintained-its-price-target-of-55
Insmed shares are trading higher after Wel...
04/04/2024 12:25:44

wells-fargo-maintains-overweight-on-insmed-maintains-55-price-target
Wells Fargo Maintains Overweight on Insmed...
04/01/2024 16:01:01

Wells Fargo analyst Tiago Fauth maintains Insmed (NASDAQ:INSM) with a Overweight and maintains $55 price target.

insmed-incorporated-to-present-nine-abstracts-from-across-its-respiratory-portfolio-at-american-thoracic-society-2024-international-conference
Insmed Incorporated To Present Nine Abstra...
03/27/2024 20:17:57

Core News & Articles
On March 8, Insmed Received Notice Of Exer...
03/11/2024 13:35:23

- SEC Filing

guggenheim-maintains-buy-on-insmed-raises-price-target-to-54
Guggenheim Maintains Buy on Insmed, Raises...
02/27/2024 17:12:40

Guggenheim analyst Vamil Divan maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $52 to $54.

ubs-initiates-coverage-on-insmed-with-buy-rating-announces-price-target-of-46
UBS Initiates Coverage On Insmed with Buy ...
02/27/2024 10:42:02

UBS analyst Trung Huynh initiates coverage on Insmed (NASDAQ:INSM) with a Buy rating and announces Price Target of $46.

insmed-q4-2023-adj-eps-128-misses-115-estimate-sales-8370m-beat-8276m-estimate
Insmed Q4 2023 Adj EPS $(1.28) Misses $(1....
02/22/2024 12:03:17

Insmed (NASDAQ:INSM) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(1.15) by 1...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION